Skip directly to page options Skip directly to A-Z link
Volume 22, Number 2—February 2016
Research

Prognostic Indicators for Ebola Patient Survival

Samuel J. Crowe1Comments to Author , Matthew J. Maenner1Comments to Author , Solomon Kuah, Bobbie Rae Erickson, Megan Coffee, Barbara Knust, John D. Klena, Joyce Foday, Darren Hertz, Veerle Hermans, Jay Achar, Grazia M. Caleo, Michel Van Herp, César G. Albariño, Brian Amman, Alison Jane Basile, Scott Bearden, Jessica A. Belser, Eric Bergeron, Dianna Blau, Aaron C. Brault, Shelley Campbell, Mike Flint, Aridth Gibbons, Christin Goodman, Laura McMullan, Christopher D. Paddock, Brandy Russell, Johanna S. Salzer, Angela Sanchez, Tara Sealy, David Wang, Gbessay Saffa, Alhajie Turay, Stuart T. Nichol, and Jonathan S. Towner
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.J. Crowe, M.J. Maenner, B.R. Erickson, B. Knust, J. Klena, C.G. Albariño, B. Amman, J.A. Belser, E. Bergeron, D. Blau, S. Campbell, M. Flint, A. Gibbons, L. McMullan, C. Paddock, J.S. Salzer, A. Sanchez, T. Sealy, D. Wang, S.T. Nichol, J.S. Towner); International Rescue Committee, New York, New York, USA (S. Kuah, M. Coffee, D. Hertz); Ministry of Health and Sanitation, Bo Town, Sierra Leone (J. Foday, G. Saffa, A. Turay); Médecins Sans Frontières, Brussels, Belgium (V. Hermans, M. Van Herp); Médecins Sans Frontières, London, UK (J. Achar, G.M. Caleo); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (A.J. Basile, S. Bearden, A.C. Brault, C. Goodman, B. Russell)

Main Article

Table 2

Logistic regression models assessing association of patient sex, age, Ct, and time from Ebola virus disease symptom onset to healthcare facility admission with patient survival, Bo District, Sierra Leone, September 2014–January 2015*

Cohort No. patients Unadjusted
Adjusted†
OR for survival (95% CI) p value OR for survival (95% CI) p value
Primary cohort
Male, vs. female 151 0.99 (0.52–1.90) 0.98 0.96 (0.38–2.44) 0.94
Age, y, increasing, continuous 151 0.97 (0.95–0.99) 0.009 0.97 (0.94–0.99) 0.01
Age ≥20 y, vs. <20 y 151 0.54 (0.27–1.06) 0.076
Ct, decreasing, continuous 151 0.73 (0.65–0.80) <0.001
Ct <20, vs. >24 151 0.0044 (0.0002–0.0245) <0.001 0.003 (0.001–0.018) <0.001
Ct 20–24, vs. >24 151 0.12 (0.04–0.28) <0.001 0.086 (0.028–0.22) <0.001
Ct <24, vs >24 151 0.04 (0.02–0.10) <0.001
Days from symptom onset to admission 
 to any healthcare facility, increasing, 
 continuous
151
0.97 (0.87–1.08)
0.59
0.88 (0.76–1.02)
0.089
ETU subgroup
Days from symptom onset to admission 
 to ETU, increasing, continuous
99
0.95 (0.83–1.07)
0.37
0.88 (0.74–1.03)
0.11
Final 2 months subgroup
Days from symptom onset to admission 
 to isolation ward, increasing, continuous 68 0.98 (0.79–1.20) 0.84 0.85 (0.64–1.11) 0.23

*Ct, cycle threshold; ETU, Ebola treatment unit; OR, odds ratio.
†Adjusted for sex, age (continuous), and Ct (<20, 20–24, >24).

Main Article

1These authors contributed equally to this article.

Page created: January 14, 2016
Page updated: January 14, 2016
Page reviewed: January 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external